{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:04:04Z","timestamp":1747973044702,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,21]]},"DOI":"10.7759\/cureus.84587","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:42:02Z","timestamp":1747885322000},"source":"Crossref","is-referenced-by-count":0,"title":["A 62-Year-Old Male Patient With Spinal Lesions Following Fingolimod Discontinuation in the Setting of Disseminated Shingles"],"prefix":"10.7759","author":[{"given":"Michelle Y","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton C","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al.. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020, 26:1816-21. 10.1177\/1352458520970841","journal-title":"Mult Scler"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley MP","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021, 325:765-79. 10.1001\/jama.2020.26858","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli O","year":"2009","unstructured":"Yaldizli O, Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2009, 2:115-28. 10.1177\/1756285608101861","journal-title":"Ther Adv Neurol Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.84.14_supplement.P3.294","article-title":"Relapse and rebound risks after natalizumab discontinuation in patients with multiple sclerosis","volume":"84","author":"Chaves C","year":"2015","unstructured":"Chaves C, Ganguly R, Dionne C, Camac A. Relapse and rebound risks after natalizumab discontinuation in patients with multiple sclerosis. Neurology. 2015, 84:14_supplement. 10.1212\/WNL.84.14_supplement.P3.294","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry B","year":"2019","unstructured":"Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther. 2019, 8:241-50. 10.1007\/s40120-019-00160-9","journal-title":"Neurol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317730096","article-title":"A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo","volume":"3","author":"Vermersch P","year":"2017","unstructured":"Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS. A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017, 3:2055217317730096. 10.1177\/2055217317730096","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105134","article-title":"Frequency and risk factors of rebound after fingolimod discontinuation - a retrospective study","volume":"81","author":"Maunula A","year":"2024","unstructured":"Maunula A, Atula S, Laakso SM, Tienari PJ. Frequency and risk factors of rebound after fingolimod discontinuation - a retrospective study. Mult Scler Relat Disord. 2024, 81:105134. 10.1016\/j.msard.2023.105134","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103278","article-title":"Factors associated with fingolimod rebound: a single center real-life experience","volume":"56","author":"Goncuoglu C","year":"2021","unstructured":"Goncuoglu C, Tuncer A, Bayraktar-Ekincioglu A, et al.. Factors associated with fingolimod rebound: a single center real-life experience. Mult Scler Relat Disord. 2021, 56:103278. 10.1016\/j.msard.2021.103278","journal-title":"Mult Scler Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103329","article-title":"Rebound activity after fingolimod cessation: a case-control study","volume":"57","author":"Barboza A","year":"2022","unstructured":"Barboza A, Gait\u00e1n MI, Alonso R, et al.. Rebound activity after fingolimod cessation: a case-control study. Mult Scler Relat Disord. 2022, 57:103329. 10.1016\/j.msard.2021.103329","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger B","year":"2015","unstructured":"Berger B, Baumgartner A, Rauer S, Mader I, Luetzen N, Farenkopf U, Stich O. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol. 2015, 282:118-22. 10.1016\/j.jneuroim.2015.03.022","journal-title":"J Neuroimmunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau J","year":"2018","unstructured":"Frau J, Sormani MP, Signori A, et al.. Clinical activity after fingolimod cessation: disease reactivation or rebound?. Eur J Neurol. 2018, 25:1270-5. 10.1111\/ene.13694","journal-title":"Eur J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher SE","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016, 73:790-4. 10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000566","article-title":"Different MRI patterns in MS worsening after stopping fingolimod","volume":"6","author":"Lapucci C","year":"2019","unstructured":"Lapucci C, Baroncini D, Cellerino M, et al.. Different MRI patterns in MS worsening after stopping fingolimod. Neurol Neuroimmunol Neuroinflamm. 2019, 6:e566. 10.1212\/NXI.0000000000000566","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419846818","article-title":"Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases","volume":"12","author":"Schmidt S","year":"2019","unstructured":"Schmidt S, Schulten T. Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases. Ther Adv Neurol Disord. 2019, 12:1756286419846818. 10.1177\/1756286419846818","journal-title":"Ther Adv Neurol Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000154","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu U","year":"2018","unstructured":"Uygunoglu U, Tutuncu M, Altintas A, Saip S, Siva A. Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation. Neurologist. 2018, 23:12-6. 10.1097\/NRL.0000000000000154","journal-title":"Neurologist"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/11596550-000000000-00000","article-title":"Clinical pharmacokinetics of fingolimod","volume":"51","author":"David OJ","year":"2012","unstructured":"David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012, 51:15-28. 10.2165\/11596550-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone L","year":"2015","unstructured":"Cavone L, Felici R, Lapucci A, et al.. Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. Brain Behav Immun. 2015, 50:78-86. 10.1016\/j.bbi.2015.06.019","journal-title":"Brain Behav Immun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri M","year":"2017","unstructured":"Ghadiri M, Fitz-Gerald L, Rezk A, et al.. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Mult Scler. 2017, 23:1225-32. 10.1177\/1352458517713147","journal-title":"Mult Scler"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2013.12.020","article-title":"The participation of varicella zoster virus in relapses of multiple sclerosis","volume":"119","author":"Sotelo J","year":"2014","unstructured":"Sotelo J, Ordo\u00f1ez G, Pineda B, Flores J. The participation of varicella zoster virus in relapses of multiple sclerosis. Clin Neurol Neurosurg. 2014, 119:44-8. 10.1016\/j.clineuro.2013.12.020","journal-title":"Clin Neurol Neurosurg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.34158","article-title":"The high prevalence of the varicella zoster virus in patients with relapsing-remitting multiple sclerosis: a case-control study in the north of Iran","volume":"9","author":"Najafi S","year":"2016","unstructured":"Najafi S, Ghane M, Yousefzadeh-Chabok S, Amiri M. The high prevalence of the varicella zoster virus in patients with relapsing-remitting multiple sclerosis: a case-control study in the north of Iran. Jundishapur J Microbiol. 2016, 9:e34158. 10.5812\/jjm.34158","journal-title":"Jundishapur J Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102939","article-title":"COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies","volume":"52","author":"Garjani A","year":"2021","unstructured":"Garjani A, Middleton RM, Hunter R, et al.. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. 2021, 52:102939. 10.1016\/j.msard.2021.102939","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102947","article-title":"Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study","volume":"52","author":"Barzegar M","year":"2021","unstructured":"Barzegar M, Vaheb S, Mirmosayyeb O, Afshari-Safavi A, Nehzat N, Shaygannejad V. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Mult Scler Relat Disord. 2021, 52:102947. 10.1016\/j.msard.2021.102947","journal-title":"Mult Scler Relat Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871276","article-title":"SARS-CoV-2 and multiple sclerosis: potential for disease exacerbation","volume":"13","author":"MacDougall M","year":"2022","unstructured":"MacDougall M, El-Hajj Sleiman J, Beauchemin P, Rangachari M. SARS-CoV-2 and multiple sclerosis: potential for disease exacerbation. Front Immunol. 2022, 13:871276. 10.3389\/fimmu.2022.871276","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363635-a-62-year-old-male-patient-with-spinal-lesions-following-fingolimod-discontinuation-in-the-setting-of-disseminated-shingles","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:42:03Z","timestamp":1747885323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363635-a-62-year-old-male-patient-with-spinal-lesions-following-fingolimod-discontinuation-in-the-setting-of-disseminated-shingles"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.84587","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}